OBJECTIVES: In the Czech Republic (CZ) extensive price regulation and prescribing conditions are common instruments often employed with new drugs. Since the introduction of statins onto the market in 1990s the originally strict conditions gradually relaxed while the prescription rates and public costs were rising. The aim was to analyze long-term utilization trends of statins, changes in their reimbursement prices and prescribing conditions, and the evolution of the market. METHODS: From January 1997 to December 2013 statin use was measured in terms of defined daily doses per 1000 insured per day (DDD/TID). The prescription-based database of the General Health Insurance Company of the Czech Republic in 1997 covering 7825,216 inhabitants, i.e. 76% of CZ population, was used as the administrative data source. Also the overall expenditure, unit prices, and reimbursement criteria were analyzed. RESULTS: Between 1997 and 2013 the utilization of statins rose from 2 to 96 DDD/TID while the expenditure rose 5.5-fold. The rise of prescription for each molecule was always observed after the liberation of the prescribing criteria. In the study period reimbursement prices of simvastatin and atorvastatin gradually decreased to just 5% of their initial values. CONCLUSIONS: The rising consumption of statins in CZ clearly corresponds in time with the liberation of prescribing conditions allowing for prescription by general practitioners and with the introduction of generics accompanied by a swift and repeated reimbursement price cuts.

Department of Social and Clinical Pharmacy Faculty of Pharmacy Charles University Prague Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc17014302

003      

CZ-PrNML

005      

20170428110328.0

007      

ta

008      

170413s2015 ie f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.healthpol.2015.02.016 $2 doi

035    __

$a (PubMed)25929214

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ie

100    1_

$a Fuksa, Leos $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. Electronic address: fuksl9aa@faf.cuni.cz.

245    14

$a The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013 / $c L. Fuksa, M. Vocelka, M. Vytrisalova,

520    9_

$a OBJECTIVES: In the Czech Republic (CZ) extensive price regulation and prescribing conditions are common instruments often employed with new drugs. Since the introduction of statins onto the market in 1990s the originally strict conditions gradually relaxed while the prescription rates and public costs were rising. The aim was to analyze long-term utilization trends of statins, changes in their reimbursement prices and prescribing conditions, and the evolution of the market. METHODS: From January 1997 to December 2013 statin use was measured in terms of defined daily doses per 1000 insured per day (DDD/TID). The prescription-based database of the General Health Insurance Company of the Czech Republic in 1997 covering 7825,216 inhabitants, i.e. 76% of CZ population, was used as the administrative data source. Also the overall expenditure, unit prices, and reimbursement criteria were analyzed. RESULTS: Between 1997 and 2013 the utilization of statins rose from 2 to 96 DDD/TID while the expenditure rose 5.5-fold. The rise of prescription for each molecule was always observed after the liberation of the prescribing criteria. In the study period reimbursement prices of simvastatin and atorvastatin gradually decreased to just 5% of their initial values. CONCLUSIONS: The rising consumption of statins in CZ clearly corresponds in time with the liberation of prescribing conditions allowing for prescription by general practitioners and with the introduction of generics accompanied by a swift and repeated reimbursement price cuts.

650    _2

$a atorvastatin $x ekonomika $x terapeutické užití $7 D000069059

650    _2

$a Česká republika $7 D018153

650    _2

$a náklady na léky $x statistika a číselné údaje $7 D016527

650    _2

$a náhrada léků $x ekonomika $7 D057915

650    _2

$a zdravotní politika $x ekonomika $7 D006291

650    _2

$a lidé $7 D006801

650    _2

$a statiny $x ekonomika $x terapeutické užití $7 D019161

650    _2

$a zdravotní pojištění $x ekonomika $7 D007348

650    _2

$a lékařská praxe - způsoby provádění $x ekonomika $x statistika a číselné údaje $7 D010818

650    _2

$a dávkové mechanismy $x ekonomika $7 D012051

650    _2

$a simvastatin $x ekonomika $x terapeutické užití $7 D019821

655    _2

$a časopisecké články $7 D016428

700    1_

$a Vocelka, Milan $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. Electronic address: vocelka.milan@gmail.com.

700    1_

$a Vytrisalova, Magda $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. Electronic address: magda.vytrisalova@faf.cuni.cz.

773    0_

$w MED00001995 $t Health policy (Amsterdam, Netherlands) $x 1872-6054 $g Roč. 119, č. 9 (2015), s. 1255-64

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25929214 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20170413 $b ABA008

991    __

$a 20170428110649 $b ABA008

999    __

$a ok $b bmc $g 1200767 $s 975080

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 119 $c 9 $d 1255-64 $e 20150324 $i 1872-6054 $m Health policy $n Health Policy $x MED00001995

LZP    __

$a Pubmed-20170413